OA10362A - Protéines obèses (ob) recombinantes - Google Patents
Protéines obèses (ob) recombinantes Download PDFInfo
- Publication number
- OA10362A OA10362A OA60824D OA60824D OA10362A OA 10362 A OA10362 A OA 10362A OA 60824 D OA60824 D OA 60824D OA 60824 D OA60824 D OA 60824D OA 10362 A OA10362 A OA 10362A
- Authority
- OA
- OAPI
- Prior art keywords
- protein
- human
- murine
- seq
- obese
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Child & Adolescent Psychology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43577795A | 1995-05-05 | 1995-05-05 | |
US48462995A | 1995-06-07 | 1995-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA10362A true OA10362A (fr) | 2001-11-15 |
Family
ID=27030682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA60824D OA10362A (fr) | 1995-05-05 | 1996-05-03 | Protéines obèses (ob) recombinantes |
Country Status (35)
Country | Link |
---|---|
US (1) | US6025325A (bg) |
EP (1) | EP0741187A2 (bg) |
JP (1) | JP3244627B2 (bg) |
KR (1) | KR100219970B1 (bg) |
CN (1) | CN1157290A (bg) |
AR (1) | AR003087A1 (bg) |
AU (1) | AU688210B2 (bg) |
BG (1) | BG62975B1 (bg) |
BR (1) | BR9602166A (bg) |
CA (1) | CA2175298A1 (bg) |
CZ (1) | CZ129796A3 (bg) |
DE (1) | DE741187T1 (bg) |
ES (1) | ES2093593T1 (bg) |
GR (1) | GR960300075T1 (bg) |
HR (1) | HRP960213A2 (bg) |
HU (1) | HU220093B (bg) |
IL (1) | IL118059A0 (bg) |
IS (1) | IS4343A (bg) |
MA (1) | MA23856A1 (bg) |
MY (1) | MY132189A (bg) |
NO (1) | NO961796L (bg) |
NZ (1) | NZ286466A (bg) |
OA (1) | OA10362A (bg) |
PE (1) | PE50897A1 (bg) |
PL (1) | PL186568B1 (bg) |
RO (1) | RO117177B1 (bg) |
RU (1) | RU96109211A (bg) |
SG (1) | SG49337A1 (bg) |
SK (1) | SK56996A3 (bg) |
SV (1) | SV1996000030A (bg) |
TN (1) | TNSN96066A1 (bg) |
TR (1) | TR199600357A2 (bg) |
TW (1) | TW464655B (bg) |
UY (1) | UY24219A1 (bg) |
YU (1) | YU26596A (bg) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6150328A (en) | 1986-07-01 | 2000-11-21 | Genetics Institute, Inc. | BMP products |
AU674500B2 (en) | 1991-11-04 | 1997-01-02 | Genetics Institute, Llc | Recombinant bone morphogenetic protein heterodimers, compositions and methods of use |
US6479055B1 (en) * | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
US6291206B1 (en) | 1993-09-17 | 2001-09-18 | Genetics Institute, Inc. | BMP receptor proteins |
DK0733109T3 (da) | 1993-12-07 | 2006-07-03 | Genetics Inst Llc | BMP-12, BMP-13 og seneinducerende præparater dermed |
US6471956B1 (en) | 1994-08-17 | 2002-10-29 | The Rockefeller University | Ob polypeptides, modified forms and compositions thereto |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US6124448A (en) * | 1994-08-17 | 2000-09-26 | The Rockfeller University | Nucleic acid primers and probes for the mammalian OB gene |
US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
US6048837A (en) * | 1994-08-17 | 2000-04-11 | The Rockefeller University | OB polypeptides as modulators of body weight |
US6350730B1 (en) | 1994-08-17 | 2002-02-26 | The Rockefeller University | OB polypeptides and modified forms as modulators of body weight |
US6429290B1 (en) | 1994-08-17 | 2002-08-06 | The Rockefeller University | OB polypeptides, modified forms and derivatives |
US6936439B2 (en) * | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
US20030040467A1 (en) * | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
BR9612359A (pt) * | 1995-12-27 | 1999-07-13 | Genentech Inc | Derivado covalente de uma proteína ob composição polipeptídeo quimérico sequência de ácido nucleico vetor de express o replicável célula hospedeira e métodos associados aos mesmos |
AU769250B2 (en) * | 1995-12-27 | 2004-01-22 | Genentech Inc. | OB protein derivatives having prolonged half-life |
US20050019325A1 (en) | 1996-01-08 | 2005-01-27 | Carter Paul J. | WSX receptor agonist antibodies |
US7074397B1 (en) * | 1996-01-08 | 2006-07-11 | Genentech, Inc. | Method for enhancing proliferation or differentiation of a cell using ob protein |
US6541604B1 (en) * | 1996-01-08 | 2003-04-01 | Genentech, Inc. | Leptin receptor having a WSX motif |
EP0877627A1 (en) * | 1996-01-25 | 1998-11-18 | Eli Lilly And Company | Obesity protein analog compounds and formulations thereof |
US7067472B1 (en) * | 1996-06-04 | 2006-06-27 | The Scripps Research Institute | Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies |
US6001816A (en) * | 1996-06-20 | 1999-12-14 | Merck & Co., Inc. | Gene therapy for leptin deficiency |
US20060205660A1 (en) * | 1996-06-20 | 2006-09-14 | Sauvage Frederic D | OB protein-immunoglobulin chimeras |
US20030036629A1 (en) * | 1997-12-12 | 2003-02-20 | Barry Foster | Novel tgf-beta protein purification methods |
US6656906B1 (en) * | 1998-05-20 | 2003-12-02 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
US6727224B1 (en) | 1999-02-01 | 2004-04-27 | Genetics Institute, Llc. | Methods and compositions for healing and repair of articular cartilage |
US7169889B1 (en) * | 1999-06-19 | 2007-01-30 | Biocon Limited | Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin |
CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
JO2291B1 (en) | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
ES2225241T3 (es) | 1999-10-15 | 2005-03-16 | Genetics Institute, Llc | Formulaciones de acido hialuronico para suministrar proteinas osteogenicas. |
WO2001096565A2 (en) * | 2000-06-16 | 2001-12-20 | Asterion Limited | Binding agents: chimeric ligand/receptor proteins |
US20030054015A1 (en) * | 2000-12-25 | 2003-03-20 | Shinichiro Haze | Sympathetic-activating perfume composition |
US6867183B2 (en) * | 2001-02-15 | 2005-03-15 | Nobex Corporation | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
EP1234583A1 (en) | 2001-02-23 | 2002-08-28 | F. Hoffmann-La Roche Ag | PEG-conjugates of HGF-NK4 |
JP2005500280A (ja) | 2001-06-01 | 2005-01-06 | ワイエス | 骨形成タンパク質(bmp)をコードする配列の全身投与のための組成物および方法 |
US6828297B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
US6828305B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7713932B2 (en) | 2001-06-04 | 2010-05-11 | Biocon Limited | Calcitonin drug-oligomer conjugates, and uses thereof |
US6713452B2 (en) | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
TWI267378B (en) | 2001-06-08 | 2006-12-01 | Wyeth Corp | Calcium phosphate delivery vehicles for osteoinductive proteins |
US7196059B2 (en) * | 2001-09-07 | 2007-03-27 | Biocon Limited | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
US7166571B2 (en) * | 2001-09-07 | 2007-01-23 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7312192B2 (en) * | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
US7030082B2 (en) * | 2001-09-07 | 2006-04-18 | Nobex Corporation | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith |
US6913903B2 (en) * | 2001-09-07 | 2005-07-05 | Nobex Corporation | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
ES2350924T3 (es) | 2001-10-22 | 2011-01-28 | Amgen, Inc. | Uso de leptina para el tratamiento de la lipoatrofia humana y método para determinar la predisposición a dicho tratamiento. |
AU2003225277A1 (en) * | 2002-05-02 | 2003-11-17 | Robert Harris | Lipid removal from the body |
WO2003105768A2 (en) | 2002-06-13 | 2003-12-24 | Nobex Corporation | Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus |
DE602004005477T2 (de) | 2003-09-12 | 2007-12-13 | Wyeth | Injizierbare feste Calciumphosphat-Stäbe zur Abgabe von osteogenen Proteinen |
AU2005269753B2 (en) | 2004-07-19 | 2011-08-18 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof |
US8227408B2 (en) * | 2005-09-07 | 2012-07-24 | Neurotez, Inc. | Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology |
US8716220B2 (en) * | 2005-09-07 | 2014-05-06 | Nikolaos Tezapsidis | Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta |
ES2664822T3 (es) * | 2007-10-16 | 2018-04-23 | Biocon Limited | Una composición farmacéutica sólida administrable por vía oral y un proceso de la misma |
EP2326339A4 (en) * | 2008-05-21 | 2012-06-20 | Neurotez Inc | METHOD FOR TREATING PROGRESSIVE COGNITIVE DISORDER IN CONNECTION WITH NEUROFIBRILLARY TANGLES |
JP2012523434A (ja) | 2009-04-10 | 2012-10-04 | アミリン・ファーマシューティカルズ,インコーポレイテッド | エストロゲン欠乏哺乳類のためのアミリンアゴニスト化合物 |
PT2621519T (pt) | 2010-09-28 | 2017-10-04 | Aegerion Pharmaceuticals Inc | Polipéptido de fusão de leptina-abd com duração de ação melhorada |
EP2667899A1 (en) | 2011-01-26 | 2013-12-04 | Novo Nordisk A/S | Leptin derivatives |
US12139555B2 (en) * | 2019-12-03 | 2024-11-12 | Rodan & Fields, Llc | Peptides and compositions for inhibiting hair growth |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4199337A (en) * | 1978-10-06 | 1980-04-22 | International Telephone And Telegraph Corporation | Method of fabricating high strength optical preforms |
US4666836A (en) * | 1981-01-02 | 1987-05-19 | The Research Foundation Of State University Of New York | Novel cloning vehicles for polypeptide expression in microbial hosts |
US4609546A (en) * | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
US4643969A (en) * | 1983-07-25 | 1987-02-17 | The Research Foundation Of State University Of New York | Novel cloning vehicles for polypeptide expression in microbial hosts |
US4757013A (en) * | 1983-07-25 | 1988-07-12 | The Research Foundation Of State University Of New York | Cloning vehicles for polypeptide expression in microbial hosts |
EP0154316B1 (en) * | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5643575A (en) * | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
AU3329895A (en) * | 1994-08-17 | 1996-03-07 | Rockefeller University, The | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US6309853B1 (en) * | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US5861485A (en) * | 1994-08-23 | 1999-01-19 | Millennium Pharmaceuticals, Inc. | Polypeptides involved in body weight disorders, including obesity |
US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5827734A (en) * | 1995-01-20 | 1998-10-27 | University Of Washington | Materials and methods for determining ob protein in a biological sample |
US5559208A (en) * | 1995-01-31 | 1996-09-24 | Eli Lilly And Company | Anti-obesity proteins |
US5574133A (en) * | 1995-01-31 | 1996-11-12 | Eli Lilly And Company | Anti-obesity proteins |
US5563245A (en) * | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
US5567803A (en) * | 1995-01-31 | 1996-10-22 | Eli Lilly And Company | Anti-obesity proteins |
US5569744A (en) * | 1995-01-31 | 1996-10-29 | Eli Lilly And Company | Anti-obesity proteins |
WO1996023517A1 (en) * | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Anti-obesity proteins |
US5569743A (en) * | 1995-01-31 | 1996-10-29 | Eli Lilly And Company | Anti-obesity proteins |
US5563244A (en) * | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
US5563243A (en) * | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
US5594104A (en) * | 1995-01-31 | 1997-01-14 | Eli Lilly And Company | Anti-obesity proteins |
US5567678A (en) * | 1995-01-31 | 1996-10-22 | Eli Lilly And Company | Anti-obesity proteins |
US5580954A (en) * | 1995-01-31 | 1996-12-03 | Eli Lilly And Company | Anti-obesity proteins |
US5554727A (en) * | 1995-01-31 | 1996-09-10 | Eli Lilly And Company | Anti-obesity proteins |
AU5539596A (en) * | 1995-04-06 | 1996-10-23 | Amylin Pharmaceuticals, Inc. | Anti-obesity agents |
CA2223433C (en) * | 1995-06-07 | 2003-11-18 | Amgen Inc. | Ob protein compositions and methods |
WO1997020933A2 (en) * | 1995-12-06 | 1997-06-12 | Schering Corporation | MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS |
BR9612359A (pt) * | 1995-12-27 | 1999-07-13 | Genentech Inc | Derivado covalente de uma proteína ob composição polipeptídeo quimérico sequência de ácido nucleico vetor de express o replicável célula hospedeira e métodos associados aos mesmos |
-
1996
- 1996-04-24 DE DE0741187T patent/DE741187T1/de active Pending
- 1996-04-24 EP EP96106408A patent/EP0741187A2/en not_active Ceased
- 1996-04-24 ES ES96106408T patent/ES2093593T1/es active Pending
- 1996-04-29 CA CA002175298A patent/CA2175298A1/en not_active Abandoned
- 1996-04-29 NZ NZ286466A patent/NZ286466A/en unknown
- 1996-04-29 IL IL11805996A patent/IL118059A0/xx unknown
- 1996-04-29 HU HU9601120A patent/HU220093B/hu not_active IP Right Cessation
- 1996-04-30 PL PL96314051A patent/PL186568B1/pl unknown
- 1996-04-30 RU RU96109211/04A patent/RU96109211A/ru not_active Application Discontinuation
- 1996-04-30 AU AU51978/96A patent/AU688210B2/en not_active Withdrawn - After Issue
- 1996-05-02 SG SG1996009690A patent/SG49337A1/en unknown
- 1996-05-02 HR HR08/484,629A patent/HRP960213A2/hr not_active Application Discontinuation
- 1996-05-02 AR ARP960102430A patent/AR003087A1/es not_active Application Discontinuation
- 1996-05-02 PE PE1996000300A patent/PE50897A1/es not_active Application Discontinuation
- 1996-05-02 MA MA24221A patent/MA23856A1/fr unknown
- 1996-05-03 IS IS4343A patent/IS4343A/is unknown
- 1996-05-03 UY UY24219A patent/UY24219A1/es unknown
- 1996-05-03 RO RO96-00920A patent/RO117177B1/ro unknown
- 1996-05-03 TN TNTNSN96066A patent/TNSN96066A1/fr unknown
- 1996-05-03 SK SK569-96A patent/SK56996A3/sk unknown
- 1996-05-03 BG BG100558A patent/BG62975B1/bg unknown
- 1996-05-03 MY MYPI96001683A patent/MY132189A/en unknown
- 1996-05-03 OA OA60824D patent/OA10362A/fr unknown
- 1996-05-03 CN CN96104497A patent/CN1157290A/zh active Pending
- 1996-05-03 TR TR96/00357A patent/TR199600357A2/xx unknown
- 1996-05-03 CZ CZ961297A patent/CZ129796A3/cs unknown
- 1996-05-03 SV SV1996000030A patent/SV1996000030A/es not_active Application Discontinuation
- 1996-05-03 NO NO961796A patent/NO961796L/no not_active Application Discontinuation
- 1996-05-04 TW TW085105350A patent/TW464655B/zh not_active IP Right Cessation
- 1996-05-04 KR KR1019960014570A patent/KR100219970B1/ko not_active IP Right Cessation
- 1996-05-06 YU YU26596A patent/YU26596A/sh unknown
- 1996-05-06 BR BR9602166A patent/BR9602166A/pt not_active Application Discontinuation
- 1996-05-07 JP JP11273996A patent/JP3244627B2/ja not_active Expired - Fee Related
- 1996-05-15 US US08/648,263 patent/US6025325A/en not_active Expired - Fee Related
- 1996-12-31 GR GR960300075T patent/GR960300075T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
OA10362A (fr) | Protéines obèses (ob) recombinantes | |
EP1135168B1 (fr) | Vecteurs peptidiques de substances a travers la barriere hemato-encephalique | |
HUT70309A (en) | Production and use of multimeric hemoglobins | |
HU229068B1 (hu) | Urát oxidáz változatok és alkalmazásuk | |
JP2017518298A (ja) | インスリン及びglp−1/グルカゴン二重アゴニストを含む糖尿病治療用組成物 | |
CA2184841C (fr) | Adenovirus recombinants codant pour le facteur neurotrophique des cellules gliales (gdnf) | |
WO1993015211A1 (fr) | Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant | |
HU229626B1 (hu) | Urát oxidáz változat és alkalmazása | |
JP2002531050A (ja) | 抗メチオニンおよび抗ホモシステイン化学療法におけるメチオニナーゼの使用 | |
EP0537166B1 (fr) | Polypeptides hydrosolubles ayant une haute affinite pour les interferons alpha et beta | |
CN112218644A (zh) | 人类犬尿氨酸酶及其用途 | |
WO1996014415A1 (fr) | Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin | |
EP1397161B1 (fr) | Composes constitues d'une molecule analgesique liee a un vecteur | |
FR2572936A1 (fr) | Nouveau lymphokine et anticorps monoclonal specifique de ce lymphokine, leurs production et utilisations | |
FR2657881A1 (fr) | Nouveaux polypeptides hydrosolubles, sequences d'adn, nouvelles cellules, procede de preparation, applications et compositions renfermant lesdits polypeptides. | |
WO1995025803A1 (fr) | ADENOVIRUS RECOMBINANTS CODANT POUR LE FACTEUR DE CROISSANCE DES FIBROBLASTES ACIDES (aFGF) | |
AU728834B3 (en) | Recombinant proteins | |
EP0139555B1 (fr) | Nouveau peptide de synthèse, son procédé de préparation et médicaments le contenant | |
AU5358399A (en) | Proteins | |
MXPA96001655A (en) | Proteins (ob) obesas recommend | |
WO1994019462A1 (fr) | Facteurs de croissance de la famille de l'harp, procede d'obtention et applications | |
CA2166298A1 (fr) | Famille de peptides appeles xenoxines | |
FR3147278A1 (fr) | Polypeptides de liaison au tnfr2 et procedes d'utilisation | |
CA2124948A1 (fr) | Cytokine antagoniste de l'ifn-gamma | |
EP1244690B1 (fr) | Procede de preparation d'un polypeptide soluble en solvant aqueux en absence de detergent |